NCT06832059

Brief Summary

The primary aim of this pilot study is to assess the feasibility of a 12-week dietary intervention combined with the use of CGM in adults with T2D. The results of the pilot study will provide insights into recruitment, design, and the effectiveness of the intervention for the future long-term (12-month) PRECISE-DIET STUDY

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable type-2-diabetes

Timeline
4mo left

Started Nov 2025

Shorter than P25 for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Nov 2025Aug 2026

First Submitted

Initial submission to the registry

January 9, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 18, 2025

Completed
9 months until next milestone

Study Start

First participant enrolled

November 18, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2026

Last Updated

February 10, 2026

Status Verified

November 1, 2025

Enrollment Period

10 months

First QC Date

January 9, 2025

Last Update Submit

February 9, 2026

Conditions

Keywords

Type 2 diabetesDietary interventionCGMcontinuous glucose monitoring

Outcome Measures

Primary Outcomes (1)

  • Fidelity testing

    Participants will be invited to a workshop to evaluate the intervention and its components. Procedures from fidelity testing will be applied in the evaluation. These specific topics will be evaluated: * Study design o Is the design appropriate? E.g., number of visits, CGM use, dietetic feedback? * Sampling strategy o E.g., how many participated, recruitment methods, sample diversity? * Treatment receipt * "What is learned?" * Is the intervention relevant to and accepted by the participants? * Treatment enactment * What is actually used and done? * Do participants' "behavioural skills" improve?

    12 weeks after baseline

Secondary Outcomes (15)

  • HbA1c (mmol/mol)

    Measured at baseline and after 12 weeks

  • Time in range (TIR)

    Measured at baseline and after 12 weeks

  • Time above range (TAR)

    Measured at baseline and after 12 weeks

  • Time below range (TBR)

    Measured at baseline and after 12 weeks

  • Coefficient of variation (CV)

    Measured at baseline and after 12 weeks

  • +10 more secondary outcomes

Other Outcomes (3)

  • Changes in glucose lowering drugs

    Measured at baseline and after 12 weeks

  • Personality trait assesment

    Baseline

  • Physical activity

    Measured at baseline and after 12 weeks

Study Arms (1)

Precise diet intervention

EXPERIMENTAL

The precise diet intervention for 12 weeks (n=20).

Other: The precise diet intervention

Interventions

The intervention includes training and education in CGM use and reduction in overall carbohydrate intake guided by individualized flexible nutrition recommendations, with adjustments made according to postprandial blood glucose responses. Staff will guide participants in the daily carbohydrate intake with personalized adjustments to accommodate individual needs by the individuals. The primary goal is to minimize the participant's time spent above 10 mmol/l

Precise diet intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • T2D
  • Diabetes duration of ≥12 months
  • ≥18 years of age
  • HbA1c ≥58 mmol/mol
  • Attending the SDCC outpatient clinic
  • Provided voluntary signed informed consent.

You may not qualify if:

  • Inability to understand the patient information.
  • Complications which do not permit to lowering HbA1c to \<58 mmol/mol.
  • Treatment with insulin.
  • Systematic use of corticosteroids.
  • Using or requiring a specialized diet (e.g., kidney diet).
  • Circumstances that affect HbA1c (e.g., liver disease and anaemia).
  • Known or suspected drug or alcohol abuse (judged by the investigator).
  • Pregnancy or breastfeeding or plans of pregnancy within the study period.
  • Participation in other clinical trials.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Steno Diabetes Center Copenhagen

Herlev, 2730, Denmark

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Bettina Ewers, PhD

    Steno Diabetes Center Copenhagen

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bettina Ewers, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Nutrition and PhD

Study Record Dates

First Submitted

January 9, 2025

First Posted

February 18, 2025

Study Start

November 18, 2025

Primary Completion (Estimated)

August 31, 2026

Study Completion (Estimated)

August 31, 2026

Last Updated

February 10, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations